FKBP51 has complex effects on BT325 glioma cells: inhibiting proliferation and sensitizing cells to BCNU, while promoting migration and invasion. The AKT and NF-κB pathways facilitate these impacts. FKBP51 may act as a predictive biomarker for glioma and a marker for how patients react to chemotherapy. Here, FKBP4 is linked to central nervous system cancer.